Physician profile
Peter Lowe
NPI 1548362833
$2,400.88
in general payments reported to CMS, 2019-2025
12 companies · $284 in 2025
The $284 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $684 · 2020: $94.40 · 2021: $279 · 2022: $354 · 2023: $366 · 2024: $339 · 2025: $284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $989.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $989.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $770.39 | 2019-2024 | Eylea Hd, Eylea |
| Genentech USA, INC. | $362.91 | 2021-2025 | Vabysmo, Susvimo |
| Astellas Pharma US INC | $231.31 | 2023-2025 | Izervay |
| Apellis Pharmaceuticals, INC. | $183.04 | 2022-2025 | Syfovre |
| Novartis Pharmaceuticals Corporation | $169.05 | 2019-2020 | |
| Allergan, INC. | $144.50 | 2019 | |
| Omeros Corporation | $125.00 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $119.27 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $115.24 | 2021 | |
| Mallinckrodt Hospital Products INC. | $107.29 | 2022 | |
| Abbvie INC. | $52.09 | 2023-2024 | |
| Eyevance Pharmaceuticals LLC | $20.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Lowe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.